-
公开(公告)号:US08278317B2
公开(公告)日:2012-10-02
申请号:US11988393
申请日:2006-07-18
IPC分类号: A61K31/4406 , A61K31/4439 , C07D401/02 , C07D413/02 , C07D213/46
CPC分类号: C07D413/06 , C07D213/56 , C07D401/06
摘要: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
摘要翻译: 本发明涉及具有用作治疗心律失常的钾通道抑制剂的结构(I)的化合物等。
-
公开(公告)号:US20090124665A1
公开(公告)日:2009-05-14
申请号:US11988393
申请日:2006-07-18
IPC分类号: A61K31/4406 , C07D213/46 , C07D413/02 , A61P9/06 , C07D401/02
CPC分类号: C07D413/06 , C07D213/56 , C07D401/06
摘要: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
摘要翻译: 本发明涉及具有用作治疗心律失常的钾通道抑制剂的结构(I)的化合物等。
-
公开(公告)号:US08501773B2
公开(公告)日:2013-08-06
申请号:US11922399
申请日:2006-06-28
IPC分类号: A01N43/42 , A01N43/40 , A61K31/47 , A61K31/445 , C07D211/00 , C07D295/00 , C07D211/08 , C07D401/00 , C07D405/00 , C07D409/00 , C07D411/00 , C07D413/00 , C07D417/00 , C07D419/00 , C07D421/00
CPC分类号: C07D211/38
摘要: The present invention is directed to 4-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
摘要翻译: 本发明涉及作为T型钙通道拮抗剂的4-氟哌啶化合物,其可用于治疗或预防涉及T型钙通道的神经和精神疾病及疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及T型钙通道的疾病中的用途。
-
公开(公告)号:US20050256117A1
公开(公告)日:2005-11-17
申请号:US10511636
申请日:2003-06-11
申请人: Meng Hsin Chen , Luping Liu , Peter Meinke , Ravi Natarajan , William Parsons , Dong-Ming Shen , Min Shu , John Stelmach , Harold Wood , Fengqi Zhang , David Wisnoski , James Doherty
发明人: Meng Hsin Chen , Luping Liu , Peter Meinke , Ravi Natarajan , William Parsons , Dong-Ming Shen , Min Shu , John Stelmach , Harold Wood , Fengqi Zhang , David Wisnoski , James Doherty
IPC分类号: A61K9/08 , A61K9/10 , A61K31/404 , A61K31/41 , A61K31/427 , A61K31/4439 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K31/7056 , A61K45/00 , A61K47/36 , A61P3/10 , A61P9/06 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/06 , A61P27/12 , A61P43/00 , C07D209/08 , C07D209/10 , C07D209/12 , C07D209/18 , C07D401/06 , C07D403/10 , C07D409/12 , C07D413/02 , C07D417/02 , C07D417/12 , C07D417/14 , C07H15/26 , C07D43/02
CPC分类号: C07D401/06 , C07D209/12 , C07D209/18 , C07D403/10 , C07D409/12 , C07D417/12 , C07D417/14 , C07H15/26
摘要: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
-
5.
公开(公告)号:US20060189764A1
公开(公告)日:2006-08-24
申请号:US10551011
申请日:2004-03-31
申请人: Craig Lindsley , David Wisnoski
发明人: Craig Lindsley , David Wisnoski
IPC分类号: C08F297/02
CPC分类号: C08F255/02 , C08F212/08 , C08F257/02 , C08F259/08 , C08F291/18 , C08F293/005 , C08F2/46
摘要: The present invention relates to a novel process for the preparation of solid-supported scavenging reagents and solid-supported functional polymers. The invention further relates to novel solid-supported functional polymers and to their use in organic synthesis and combinatorial chemistry.
-
公开(公告)号:US20070105902A1
公开(公告)日:2007-05-10
申请号:US10579261
申请日:2004-11-10
申请人: Craig Lindsley , David Wisnoski , Zhijian Zhao
发明人: Craig Lindsley , David Wisnoski , Zhijian Zhao
IPC分类号: A61K31/445 , C07D211/54 , C07D211/26
CPC分类号: C07D211/96
摘要: The present invention is directed to compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
摘要翻译: 本发明涉及抑制甘氨酸转运蛋白GlyT1的化合物,其可用于治疗与甘氨酸能或谷氨酸能神经传递功能障碍相关的神经和精神疾病以及其中涉及甘氨酸转运蛋白GlyT1的疾病。
-
公开(公告)号:US20060281803A1
公开(公告)日:2006-12-14
申请号:US10572772
申请日:2004-09-17
申请人: Craig Lindsley , David Wisnoski
发明人: Craig Lindsley , David Wisnoski
IPC分类号: C07D231/50 , A61K31/4152
CPC分类号: C07D233/88 , C07D231/40 , C07D233/90 , C07D405/12 , C07D409/04 , C07D409/12 , C07D413/12 , C07D417/12 , C07D495/04
摘要: The present invention is directed to compounds which are allosteric modulators of metabotropic glutamate receptors, including the mGluR5 receptor, and which are useful in the treatment of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
摘要翻译: 本发明涉及作为代谢型谷氨酸受体的变构调节剂(包括mGluR5受体)的化合物,它们可用于治疗与谷氨酸功能障碍相关的神经和精神病学障碍以及参与代谢型谷氨酸受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。
-
公开(公告)号:US20060235069A1
公开(公告)日:2006-10-19
申请号:US10550968
申请日:2004-03-22
申请人: Mark Duggan , Craig Lindsley , David Wisnoski
发明人: Mark Duggan , Craig Lindsley , David Wisnoski
IPC分类号: A61K31/4035 , A61K31/195 , A61K31/165 , C07D209/48
CPC分类号: C07D417/12 , C07D209/48 , C07D213/81 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D513/04
摘要: The present invention is directed to compounds which are allosteric modulators of metabotropic glutamate receptors, including the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
-
公开(公告)号:US20100216841A1
公开(公告)日:2010-08-26
申请号:US11922399
申请日:2006-06-28
IPC分类号: A61K31/445 , C07D211/34 , C07D405/06 , C07D403/06 , C07D413/06 , C07D417/06 , A61K31/453 , A61K31/454 , A61P25/00
CPC分类号: C07D211/38
摘要: The present invention is directed to 4-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
摘要翻译: 本发明涉及作为T型钙通道拮抗剂的4-氟哌啶化合物,其可用于治疗或预防涉及T型钙通道的神经和精神疾病及疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及T型钙通道的疾病中的用途。
-
公开(公告)号:US20070254880A1
公开(公告)日:2007-11-01
申请号:US10593950
申请日:2005-03-23
申请人: Wesley Blackaby , Mark Duggan , David Hallett , George Hartman , Andrew Jennings , William Leister , Richard Lewis , Craig Lindsley , Elizabeth Naylor , Leslie Street , Yi Wang , David Wisnoski , Scott Wolkenberg , Zhijian Zhao
发明人: Wesley Blackaby , Mark Duggan , David Hallett , George Hartman , Andrew Jennings , William Leister , Richard Lewis , Craig Lindsley , Elizabeth Naylor , Leslie Street , Yi Wang , David Wisnoski , Scott Wolkenberg , Zhijian Zhao
IPC分类号: A61K31/445 , A61K31/5375 , C07D211/06 , C07D413/02
CPC分类号: C07D409/14 , C07D401/04 , C07D401/14 , C07D413/14
摘要: The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
摘要翻译: 本发明涉及抑制甘氨酸转运蛋白GlyT1的吡啶基,哒嗪基,嘧啶基和吡嗪基哌啶化合物,其可用于治疗与甘氨酸能或谷氨酸能神经传递功能障碍相关的神经和精神疾病以及其中涉及甘氨酸转运蛋白GlyT1的疾病 。
-
-
-
-
-
-
-
-
-